We use cookies on this site. By browsing our site you agree to our use of cookies. Close this message Find out more

Home > About us home > News and events > News > Gene Therapy chooses rare disease expert as its new Editor-in-Chief
More in this section Articles

Gene Therapy chooses rare disease expert as its new Editor-in-Chief

Posted on 20/01/2017

Rare Disease Day: Designing a poster for Cystic Fibrosis

Royal Holloway's Dr Rafael J. Yáñez-Muñoz has been appointed Editor-in-Chief of the journal Gene Therapy, a key title for the exploration of new genetic and stem cell therapy techniques, so-called Advanced Therapies. It is published by Springer Nature.

Reader at Royal Holloway’s Advanced Gene and Cell Therapy laboratory (AGCTlab), Dr Yáñez is expert in the areas of genome editing, gene medicine and stem cells for understanding and progressing treatment of neurodegenerative and inherited diseases, including spinal muscular atrophy, spinal injury, Parkinson disease and immunodeficiencies.

Dr Yáñez is a leading authority on rare diseases, which affect over 3million people in the UK. He also leads Royal Holloway’s outreach for Rare Disease Day, a global annual event to highlight the challenges faced by those living with such diseases. Rare Disease Day also provides opportunity to celebrate collaborative research and rally support for study that provides advancement in the area. Dr Yáñez will write a special editorial for the journal on the topic for its February edition, to be published on February 23rd 2017.

Speaking of his appointment, Dr Yáñez commented, “This is a great opportunity to shape, evaluate and experience the very best research in the area of advanced therapies. This relatively new area of exploration can offer hope to those suffering from common and inherited disorders, developing solutions, support and cures for often intractable diseases.”

As part of his role Dr Yáñez will edit a special issue on the recent approval of Spinraza by the US FDA (Food and Drug Administration). This is a drug that provides a treatment for Spinal muscular atrophy, the most common genetic cause of death in infants and one of Dr Yáñez’s research interests. This edition will be published on April 20th 2017.

Learn more about applying to study at Royal Holloway's School of Biological Science.


Comment on this page

Did you find the information you were looking for? Is there a broken link or content that needs updating? Let us know so we can improve the page.

Note: If you need further information or have a question that cannot be satisfied by this page, please call our switchboard on +44 (0)1784 434455.

This window will close when you submit your comment.

Add Your Feedback